Karooooo achieves solid Q1 2024 results, delivering strong subscription revenue and subscriber growth
SINGAPORE--(BUSINESS WIRE)--Karooooo, that owns 100% of Cartrack, a leading provider of insightful real-time data analytics…
3 years ago
New Data Shows Advantages of Rapid Medical’s COMANECI™ Embolization Assist Device
World Neurosurgery meta-analysis shows fewer complications, higher occlusion rates for ruptured wide-neck intracranial aneurysms YOKNEAM,…
3 years ago
Renesas Develops Complete Power Management Solution for AMD Space-Grade Versal Adaptive SoC
Reference Design Packs Multiple Rad-Hard Core Power Rails in Ultra-Compact Footprint, Delivering Turnkey Efficiency and…
3 years ago
Interactive Brokers Offers Trading on the Taiwan Stock Exchange
IBKR Further Expands Its Global Market Access GREENWICH, Conn.--(BUSINESS WIRE)--Interactive Brokers (Nasdaq: IBKR), an automated…
3 years ago
Cyber Security Startup PingSafe Launches from Stealth with $3.3M to Outsmart Attackers
PingSafe helps companies target their biggest cloud security challenges, providing coverage for exploitable vulnerabilities. In…
3 years ago
Macnica and Dragos to Deliver OT Cybersecurity to Critical Infrastructure and Manufacturing Control Systems in Japan
HANNOVER, Md. & YOKOHAMA, Japan--(BUSINESS WIRE)--Dragos, the global leader in cybersecurity for Operational Technology (OT),…
3 years ago
Enfusion Announces Date of Second Quarter 2023 Results
NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider…
3 years ago
Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023
– Key Initiatives Highlight the Role of Catalytic Collaboration to Help Advance Health Equity –…
3 years ago
FTLife x New World CLUB CIRCLE OUR NEW WORLD
Holistic programmes to create a new lifestyle experience for individuals and families HONG KONG SAR…
3 years ago
JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients
The Phase 3 PRIME study demonstrates that treatment with ZEJULA significantly extends progression-free survival versus…
3 years ago